Fig. 3From: MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progressionMCM2, MCM6 and MCM7 immunohistological testing in normal livers (n = 60), cirrhotic livers (n = 110), and HCC (n = 175). a Tissue MCM2, MCM6 and MCM7 immunoreactivity: from negative in normal livers to weak in cirrhotic livers to strong in HCC. The patterns of MCM2 (b), MCM6 (c) and MCM7 (d) expression in normal livers, cirrhotic livers and HCC were present according to the immunoreactive intensity. All three markers were all significantly higher in HCC (P < 0.01). e ROC curves comparing MCM2 (AUC = 0.675, P < 0.001), MCM6 (AUC = 0.896, P < 0.001), and MCM7 (AUC = 0.771, P < 0.001) in HCC versus normal and cirrhotic livers. ROC, receiver operating characteristics; Neg., negative; Pos., positiveBack to article page